Dr. Reddy’s Gets FDA Advertising Letter, But Its Response Is Far From Generic

Despite changes to the website, the boxed warning about the risk of epidural or spinal hematomas for patients taking generic fondaparinux still receives little emphasis on a Dr. Reddy’s promotional page.

Although Dr. Reddy's Laboratories Ltd. has changed a website promoting its generic version of GlaxoSmithKline Inc.’s acute pulmonary embolism drug Arixtra (fondaparinux) apparently in response to an FDA “notice of violation” letter, the changes may not address the agency’s concerns.

The Dec. 22 letter from FDA's Office of Prescription Drug Promotion critiqued the old version of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Asia

Australia Looks To Modernize Human Tissue Laws, Improving Access For Researchers

 

Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.

China NMPA Lays Out Regulatory Priorities At DIA

 
• By 

At this year’s DIA China meeting, the national regulator updated its policy focus areas for this year, including clinical trial data protection and pilot projects to shorten IND approval times.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By 

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.